In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
AssigneeCelltrend GmbH
InventorsHarald Heidecke, Kai Schulze-Forster
Life of this patent
Estimating the term…
Abstract
A method for diagnosis and/or prediction of hypertension and/or cardiovascular end-organ damage is disclosed. The method disclosed comprises the determination of the presence of soluble pro-renin receptor in samples derived from a subject. Furthermore, the use of anti-sPRR antibodies in diagnosis and/or prediction of cardiovascular end-organ damage is encompassed.
Claims18
An in vitro method for diagnosis or prediction of hypertension and/or early-stage cardiovascular end-organ damage in a patient, the method comprising determining the concentration of soluble prorenin receptor (sPRR) in a sample from the patient using an antibody or antibody fragment that immunologically binds a polypeptide comprising SEQ ID NO:4 wherein the presence of the polypeptide at increased concentration compared to the concentration of such a polypeptide in samples from healthy subjects is indicative for hypertension and/or early-stage cardiovascular end-organ damage and wherein the presence of the polypeptide at decreased concentration compared to the concentration of such a polypeptide in samples from healthy subjects is indicative for late stage cardiovascular end-organ damage.
An in vitro method for determining the concentration of soluble prorenin receptor (sPRR) in a sample from a patient suspected of developing hypertension and/or early stage cardiovascular end-organ disease, the method comprising conducting an immunoassay that determines the level of a polypeptide comprising SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4 in such a sample.
Dependencies are inferred from the claim text.